目前我国乙型肝炎病毒（Hepatitis B virus，HBV）感染者诊断率和治疗率与世界卫生组织提出的"2030年消除病毒性肝炎作为公共卫生危害"目标仍有较大差距。为实现乙型病毒性肝炎全人群治疗，中国医师协会感染科医师分会、国家感染性疾病临床医学研究中心邀请国内感染病和肝炎疾病领域相关专家，在充分复习国内外相关指南与文献的基础上，共同撰写《乙型病毒性肝炎全人群管理专家共识（2023）》，以进一步扩大乙型肝炎社区筛查，规范抗病毒治疗适应群体，细化各类特殊人群乙型肝炎患者治疗，针对《慢性乙型肝炎防治指南（2022）》未覆盖人群进行临床管理，从而实现乙型病毒性肝炎的扩大筛查、应治尽治、全程管理、降本增效的目的。 There is still a substantial gap between the current diagnosis and treatment rates of hepatitis B virus (HBV) infection in China and the the goal of eliminating viral hepatitis as a major public health threat by 2030 set by World Health Organization。 In order to achieve the management of viral hepatitis type B infection in a whole population approach， the Infectious Disease Physicians Branch of Chinese Medical Doctor Association and National Clinical Research Center for Infectious Diseases invited experts in the field of infectious diseases and hepatitis diseases to jointly develop the Expert consensus on whole-population management of hepatitis B virus infection (2023) based on reviewing relevant guidelines and literature at home and abroad。 The expert consensus further simplifies the indications for antiviral treatment， refines the treatment of special types of patients， and guides the clinical management of populations not covered by Guidelines for the prevention and treatment of chronic hepatitis B (version 2022) to achieve the expanded screening and universal treatment of hepatitis B virus infection。
Expert consensus on whole-population management of hepatitis B virus infection (2023)
There is still a substantial gap between the current diagnosis and treatment rates of hepatitis B virus (HBV) infection in China and the the goal of eliminating viral hepatitis as a major public health threat by 2030 set by World Health Organization. In order to achieve the management of viral hepatitis type B infection in a whole population approach, the Infectious Disease Physicians Branch of Chinese Medical Doctor Association and National Clinical Research Center for Infectious Diseases invited experts in the field of infectious diseases and hepatitis diseases to jointly develop the Expert consensus on whole-population management of hepatitis B virus infection (2023) based on reviewing relevant guidelines and literature at home and abroad. The expert consensus further simplifies the indications for antiviral treatment, refines the treatment of special types of patients, and guides the clinical management of populations not covered by Guidelines for the prevention and treatment of chronic hepatitis B (version 2022) to achieve the expanded screening and universal treatment of hepatitis B virus infection.
Hepatitis B virusAntiviral therapyWhole populationsConsensus
万方数据
